Deutsche Bank
INFI

Deutsche Bank’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Deutsche Bank’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-52,999
Closed -$60K – 4399
2022
Q1 		$60K Sell
52,999
-5,638
-10% -$6.74K ﹤0.01% 3779
2021
Q4 		$132K Sell
58,637
-285,786
-83% -$717K ﹤0.01% 3579
2021
Q3 		$1.18M Buy
344,423
+3,296
+1% +$10.2K ﹤0.01% 2505
2021
Q2 		$1.02M Sell
341,127
-17,727
-5% -$56.1K ﹤0.01% 2756
2021
Q1 		$1.16M Buy
+358,854
New +$1.2M ﹤0.01% 2570
2018
Q2 		– Sell
-124
Closed – – 5660
2018
Q1 		$0 Sell
124
-99
-44% -$212 ﹤0.01% 5663
2017
Q4 		$0 Sell
223
-745,445
-100% -$1.55M ﹤0.01% 5202
2017
Q3 		$990K Buy
745,668
+526,472
+240% +$654K ﹤0.01% 3023
2017
Q2 		$343K Sell
219,196
-19,562
-8% -$37.7K ﹤0.01% 3653
2017
Q1 		$769K Sell
238,758
-245,117
-51% -$603K ﹤0.01% 2834
2016
Q4 		$652K Sell
483,875
-97,560
-17% -$127K ﹤0.01% 3008
2016
Q3 		$905K Buy
581,435
+270,082
+87% +$415K ﹤0.01% 2884
2016
Q2 		$410K Sell
311,353
-67,416
-18% -$315K ﹤0.01% 3404
2016
Q1 		$1.99M Sell
378,769
-79,757
-17% -$488K ﹤0.01% 2366
2015
Q4 		$3.6M Buy
458,526
+63,788
+16% +$549K ﹤0.01% 2031
2015
Q3 		$3.33M Sell
394,738
-43,483
-10% -$401K ﹤0.01% 2099
2015
Q2 		$4.8M Sell
438,221
-113,980
-21% -$1.46M ﹤0.01% 1828
2015
Q1 		$7.72M Buy
552,201
+130,852
+31% +$2M ﹤0.01% 1495
2014
Q4 		$7.11M Buy
421,349
+8,691
+2% +$127K ﹤0.01% 1682
2014
Q3 		$5.54M Buy
412,658
+28,524
+7% +$340K ﹤0.01% 1750
2014
Q2 		$4.89M Sell
384,134
-226,958
-37% -$2.36M ﹤0.01% 1836
2014
Q1 		$7.26M Sell
611,092
-68,718
-10% -$922K 0.01% 1557
2013
Q4 		$9.39M Buy
679,810
+448,697
+194% +$6.34M 0.01% 1377
2013
Q3 		$4.03M Sell
231,113
-41,096
-15% -$787K ﹤0.01% 1987
2013
Q2 		$4.4M Buy
+272,209
New +$8.42M ﹤0.01% 1701

Other funds holding INFI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GC
Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Deutsche Bank's INFI Position: Q2 2022 in Review

Deutsche Bank sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q2 2022, closing a stake of 52,999 shares — an estimated $60K sold.

Deutsche Bank first reported a position in INFI in Q2 2013 and held it in 25 quarters. The position peaked at $9.39M in Q4 2013. 77 funds tracked by Wall St. Rank hold INFI as of Q2 2022.

  • Deutsche Bank reported no remaining Infinity Pharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
  • Deutsche Bank sold 52,999 Infinity Pharmaceuticals, Inc. shares in Q2 2022, an estimated $60K.
  • Deutsche Bank first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 25 quarters.
  • Deutsche Bank's Infinity Pharmaceuticals, Inc. position peaked at $9.39M in Q4 2013.
  • 77 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q2 2022.

Based on Deutsche Bank's 13F filing for Q2 2022, filed 11 Aug 2022.